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Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, MD, USAThe two dominant models of carcinogenesis postulate stochas-
tic (clonal evolution) or hierarchic organization of tumor (cancer
stem cell model). According to the latter, at the germinal center of
tumor evolution is a cancer stem cell (CSC) which, similar to nor-
mal adult stem cells, possesses the capacity of self-renewal and a
differentiation potential.
Over the past few years, compelling evidence has emerged in
support of the hierarchic cancer model for many solid tumors
including hepatocellular cancers. The CSCs are posited to be
responsible not only for tumor initiation but also for the genera-
tion of distant metastasis and relapse after therapy. These charac-
teristics are particularly relevant for a multi-resistant tumor
entity like human hepatocellular carcinoma and may herald a
paradigm shift in the management of this deadly disease. Identi-
ﬁcation and detailed characterization of liver CSCs is therefore
imperative for improving prevention approaches, enhancing
early detection, and extending the limited treatment options.
Despite the current progress in understanding the contribution
of CSCs to the generation of heterogeneity of tumors, the molec-
ular complexity and exact regulation of CSCs is poorly under-
stood. This review focuses on the genetic and epigenetic
mechanisms that regulate and deﬁne the unique CSC properties
with an emphasis on key regulatory pathways of liver CSCs and
their clinical signiﬁcance.
 2010 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver.Introduction
Two general models of carcinogenesis exist: the stochastic and
hierarchic cancer model. According to the traditional clonal evo-
lution model, tumor formation is the consequence of accumulat-
ing random genetic events in any normal differentiated cell
whereas the cancer stem cell (CSC) model postulates that a sin-
gle CSC gives rise to a hierarchic organization within a tumor
[1,2]. Even though the concept of a rare group of cells being
responsible for tumor initiation in vitro and in vivo is not new,Journal of Hepatology 20
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has emerged in the last decade [3–9]. The stochastic and hierar-
chic cancer models were thought to be mutually exclusive,
although current ﬁndings favor a likelihood of the complemen-
tary co-existence based on the assumption that cancer is a
genetically generated disease that is maintained and tightly reg-
ulated by epigenetic changes (Fig. 1). Similar to the phenotypic
diversity of normal adult tissues that is generated by tissue spe-
ciﬁc stem cells, the CSC model posits that at the apex of tumor
formation is a stem-like cell (commonly referred to as CSC or
tumor-initiating cell) that is responsible for the heterogeneity
observed within the clonally derived tumors including liver can-
cer [9,1,10,2]. Despite functional similarities with the adult tis-
sue stem cells, including the fundamental properties of self-
renewal and differentiation capacity, the term CSC does not con-
sider the origin of these cells [11].
The CSC model predicts several possible scenarios of how
cancer stem cells and tumor heterogeneity may originate
[9,12], including (i) differentiation arrest of adult tissue stem
cell and/or progenitor cell, (ii) dedifferentiation of mature cell,
and (iii) transdifferentiation of a stem cell from a different tis-
sue, e.g. bone marrow. (For a more detailed discussion of the
potential origin of CSC, we refer to recent reviews [13–15]).
The relative contribution of each scenario may vary depending
on factors, such as type of cancer, microenvironment, the con-
tributing mutagen(s), and/or a combination of these factors
[13].
Notably, the concept of a hierarchic tumor organization has
important clinical implications that include diagnosis, preven-
tion, and most importantly therapy [16]. Thus, deﬁning CSC-spe-
ciﬁc biomarkers may contribute to early diagnosis while
identiﬁcation of cell of origin (‘‘cell-at-risk”) is required for effec-
tive reduction of the CSC numbers. Classical therapeutic regimens
target predominantly the proliferating cells, which are unlikely to
be CSCs. Similarly, new generation therapies (e.g. sorafenib) seem
not to target the CSC as evidenced by frequent tumor relapse and
resistance after therapy [17–22]. The eradication of tumors with
hierarchic organization would require the development of new
therapies directed towards the CSCs. This implies a detailed
understanding of the fundamental CSC properties, such as self-
renewal, differentiation, chemoresistance, and, most importantly,
unraveling the underlying regulatory pathways and molecular,
genetic, and epigenetic mechanisms responsible for tumor
initiation, seeding of metastasis, and local recurrence which are
currently attributed to the CSC [12,23]. This review focuses
on the existing evidence for the role of CSC in liver cancer and10 vol. 53 j 568–577
Table 1. Cancer stem cell properties.
Fig. 1. CSC properties and mechanisms of regulation. The Cancer Stem Cell
(CSC) hypothesis places CSCs at the center of neoplastic development. The
scheme simpliﬁes our understanding of how CSCs are regulated and emphasizes
the contribution of both genetics and epigenetics in tumor initiation, develop-
ment of metastasis, and tumor relapse. CSCs share the fundamental properties of
normal stem cells, including regulatory pathways (representative molecules are
shown) and the ability to undergo symmetric (self-renewal) and asymmetric
(pluripotency) division. The unique features of CSCs (arrows) provide attractive
targets (red arrows) for developing novel therapeutic tools directed speciﬁcally at
the CSC. RNAi, RNA interference machinery; LOH, loss of heterozygosity; CNV,
copy number variations; SNP, single nucleotide polymorphism.
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provides an overview of the current approaches for the prospec-
tive isolation and regulation of CSC. The clinical implications of
the CSC model for the management of human HCC as well as crit-
ical issues and questions in the ﬁeld of liver CSC are also
addressed.
Over the last decade, there is increasing understanding 
of the hierarchic organization in hepatocellular cancers
with the cancer stem cells (CSCs) responsible for tumor 
initiation, generation of metastasis, and relapse after 
therapy
The cancer stem cells (CSCs) rest on the apex of tumor 
formation and share functional properties ascribed to the 
normal tissue stem cells,including self-renewal,
proliferation, and differentation capacity thereby leading 
to tumor heterogeneity 
Currently, isolation of liver CSCs relies on their antigenic 
(e.g. CD133,CD90, EpCAM) or functional (e.g. Side-
Population, ALDH1-Activity, Sphere formation and 
Asymmetric Cell Division) properties
Eradication of tumors with hierarchic organization would 
require the development of new therapies specifically 
directed against the CSCs and their regulatory 
mechanisms 
Aberrant gene expression in CSCs is linked to genetic 
and epigenetic deregulation of key signaling pathways 
controlling stem cell maintenance,self-renewal and 
pluripotency, such as WNT/β-Catenin, TGF-β, Hedgehog, 
and MYC   
Activation of these pathways in the CSC reflects the clinical 
behavior of the tumors and makes CSCs the prime target 
for efficient CSC eradication  
Key points Property Deﬁnition Assay
Self-renewal The ability to undergo symmetric
division
Re-plating
assays
and thereby indeﬁnitely
replenish itself
Serial
transplantations
Differentiation
capacity
The ability to undergo
asymmetric division
Differentiation
assays in vitro
and thereby recapitulate all
tumor cell types
Transplantation
Tumor
initiation/
metastasis
The ability to propagate tumor
when transplanted into the
proper environment
Sphere
formation
Invasion assays
Transplantation
Relapse The property of resistance to
different therapies and the
ability to relapse
Chemo/radio-
resistance
assaysIdentiﬁcation of cancer stem cells in liver cancer
Cancer stem cells are deﬁned by (1) self-renewing capacity; (2)
differentiation capacity; and (3) tumor-initiating capacity. Addi-
tionally, the seeding of metastasis and tumor relapse are attrib-
uted to CSC [12]. A description of the basic properties and
respective experimental assessment criteria are provided in
Table 1.
Two general approaches for the prospective isolation of CSCs
are based on their immunogenic and functional properties. The
antigenic approach utilizes a variety of cell surface markers
whereas functional isolation relies on the surrogate characteris-
tics, such as anchorage independent growth, chemo-resistance,
self-renewal, asymmetric division, and pluripotency. Functional
approaches are particularly useful when the speciﬁc CSC markers
have not been deﬁned as is the case for most CSCs. Given the
plasticity of the CSC, it is unlikely that CSCs can be deﬁned by a
single marker or functional property. Therefore, a combination
of functional and antigenic approaches seems to be the most
appropriate for identiﬁcation and isolation of CSCs.Journal of Hepatology 201Antigenic markers
A variety of markers have been successfully used to enrich for a
cancer stem cell fraction from different tumors including HCC0 vol. 53 j 568–577 569
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[24]. Of note, most of these markers also detect the surface pro-
teins on hematopoietic stem cells although it remains to be
determined how it relates to the CSC properties. The frequently
used markers for the isolation of liver CSCs include CD133,
CD90, and EpCAM.Prominin-1 (CD133)
Several recent studies on both human and mouse HCC used this
hematopoietic marker for isolating liver CSCs [25–27]. In human
HCC cell lines, the frequency of CD133-positive cells varies
between 0% and 65%. The CD133+ cells showed a greater ability
to form colonies in vitro and to initiate tumor growth in vivo.
These cells also exhibited additional stem cell characteristics,
including the expression of ‘‘stemness” genes, the capacity to
self-renew, to differentiate into non-hepatocytic lineage (angi-
omyogenic cells), and a higher chemoresistance [28]. Similar
results were obtained using a murine model in which HCC
development was driven by methionine adenosyltransferase
(MAT) deﬁciency [26,29]. Even though these studies corroborate
a potential for the CD133 marker for isolating liver CSCs in a
syngenic setting, the usefulness of a single marker may be
limited.Thy-1 (CD90)
Between 0% and 2.5% of human HCC cells were reported to be
positive for this mesenchymal stem cell marker. Yang et al.
[30,31] found that all examined tumor specimens and most of
the blood samples contained a highly tumorigenic CD90+/CD45-
cell population which was absent in normal and cirrhotic livers.
Similarly, when CD90 expression was investigated in HCC cell
lines, only the CD90+ cells were shown to be tumorigenic
[30,31]. The co-expression with the additional surface marker,
glycoprotein CD44, produced an even more aggressive pheno-
type, including a higher metastatic and self-renewing capacity
as compared to the CD90+CD44 counterpart. Antibody-induced
blockade of CD44 diminished the formation of tumors and metas-
tasis and caused apoptosis of CD90+ cells.EpCAM (epithelial cell adhesion molecule) (TACSTD1, ESA)
The surface antigen EpCAM is increasingly recognized as a spe-
ciﬁc cancer stem cell marker for a variety of tumors [32–37].
Recently, Yamashita et al. demonstrated the utility of EpCAM
for classiﬁcation of HCC patients and later conﬁrmed the differen-
tial expression of AFP and EpCAM in tumor specimens derived
from two HCC subtypes [34,38]. EpCAM+ cells isolated from
two HCC cell lines displayed CSC-like characteristics, were highly
tumorigenic in vivo and formed signiﬁcantly more spheres in
anchorage independent growth experiments than EpCAM- cells.
The CSC properties of EpCAM+ cells were further validated in
studies using primary liver tumor samples. It has been shown
that activation of Wnt/b-catenin signaling increased the EpCAM+
cell population whereas the blockage of EpCAM caused decrease
in tumorigenicity of these cells. It is important that the results of
CD90 and EpCAM studies obtained on cancer cell lines were
reproduced in fresh human HCC specimens thus providing direct
evidence for the signiﬁcance of putative cancer stem cells in
human HCC patients.570 Journal of Hepatology 201Side population approach (Hoechst-33342-dye staining)
The side population (SP) approach was developed by Goodell
et al. in 1996, and is currently widely used for isolating both
CSC and stem cells [42]. The method is based on the high activity
of the ABC membrane transporters which support the energy-
dependent substrate exportation across membranes against steep
concentration gradients thus contributing to CSC chemoresis-
tance [39]. Using HOECHST 33342 vital dye staining followed
by ﬂow cytometry analysis, a distinct population of cells actively
efﬂuxing the HOECHST dye via the ABCG2 membrane transporter
was identiﬁed. This population is known as SP which may vary in
frequency from 0% to 28% [40]. In liver cancer, a distinct SP with
CSC characteristics was ﬁrst reported by Haraguchi and col-
leagues in 2006 [41]. The group used this approach to isolate
CSC cells from various human cancer cell lines derived from the
gastrointestinal system (including liver). The SP populations were
characterized by differentially expressed markers of differentia-
tion and chemo-resistance, including ABC-transporters and CAE-
CAM6, and were able to generate both SP and non-SP cells. An
independent study by Chiba et al. later conﬁrmed the enrichment
of stem-like cells in the SP population isolated from liver cancer
cell lines. Again, SP cells expressed ‘‘stemness” markers and pos-
sessed higher proliferative potential as well as anti-apoptotic
properties in vitro than the main population of non-SP cells.
Xenograft transplantations in immunodeﬁcient animals revealed
that as little as 1000 SP cells were sufﬁcient to generate a tumor,
while 1 million non-SP cells were consistently non-tumorigenic.
Furthermore, SP cells demonstrated self-renewal capacity in
serial transplantation experiments [42]. The same group later
determined a critical role for BMI, a key molecule of the PRC2
complex important for stem cell self-renewal, in the maintenance
of liver cancer stem cells [43]. SP cells isolated from liver cancer
cell lines also exhibited metastatic potentials and therapeutic-
resistance to various drugs, similar to the properties described
for CD133+ and CD90+ cancer cells [40,41].ALDEFLUOR-approach (ALDH-activity)
Another non-immunological approach adopted from the isolation
of hematopoietic stem/progenitor cells is based on aldehyde dehy-
drogenase (ALDH) activity [41]. ALDH belongs to a ubiquitously
expressed family of enzymeswhich play a role in proliferation, dif-
ferentiation, and survival by supporting conversion of retinol to
retinoic acid. The ALDEFLOUR assay is based on the ability of ALDH
to convert the ALDH substrate BAAA (BODIPY-aminoacetalde-
hyde) into the ﬂuorescent product BAA (BODIPY-aminoacetate).
Cells with high ALDH activity become brightly ﬂuorescent (ALDH-
hi) and can be identiﬁed by ﬂow cytometry [44]. The combination
of the ADLH approach with the CD133 staining revealed a consid-
erable overlap between the ALDH+ and CD133+ cells, but not vice
versa [44]. The combination of both approaches may potentially
facilitate isolation of a more ‘‘homogeneous” CSC fraction.
Sphere formation
Sphere formation is increasingly used as a method for enrich-
ment of stem cells which relies on their property of anchorage
independent growth. In particular, the method was instrumental
in isolating neuronal stem cells [45]. Most of the assays utilize
serum-free medium containing deﬁned growth factors which0 vol. 53 j 568–577
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favors stem cell propagation and are performed under clonal con-
ditions [46]. Alternatively, a matrix-like medium (e.g. Matrigel)
can be used for investigating three dimensional growth. The con-
tribution of the sphere formation assay in the study of CSCs and
their role in liver cancer is unclear and needs further evaluation
[47,48]. Unpublished observations from our laboratory show
increased representation of CSC markers (CD133, SP) in liver can-
cer spheres as compared with monolayer cultures.Asymmetric division
CSCs, similar to normal adult stem cells, are thought to maintain
themselves through symmetric and asymmetric cell divisions.
Most recent studies are focusing on the identiﬁcation of liver
and lung CSCs by qualitatively and quantitatively assessing the
co-segregation of template DNA during mitosis, resembling the
process described in different normal tissues (ﬁbroblast, muscle,
mammary, intestinal, and neural cells) (Avital et al., personal
communication, [49]). The demonstration that CD133-positivity
co-segregated with the template DNA, while differentiation
markers were passed to the opposing daughter cell, suggested
that the fate of lung CSCs may be regulated during the cell divi-
sion process. More results from this promising method can be
expected.
In summary, the current methods used for isolating CSCs from
primary liver tumors and established tumor cell lines allow for
enrichment of cells displaying CSC properties including self-
renewal, multipotency, and extensive proliferation capacity. Con-
sistent with the CSC hypothesis and in agreement with observa-
tions from other tumor types, the CSC-enriched fractions
comprised only a minority of the liver tumor. Importantly, gene
expression patterns and antigenic characteristics of the isolated
CSCs were vastly different suggesting that the heterogeneity of
human liver cancer may be related to heterogeneity of liver CSCs.Caveats and unresolved questions in the isolation of CSCs
The current methods used for CSC isolation have important deﬁ-
ciencies which may contribute to the inconsistencies in results
across different studies. Thus, CSC isolation by a single marker,
although attractive, may be not sufﬁciently discriminatory [33].
Also, it is frequently not clear what these markers really ‘‘mark”.
Antibody and/or dye dependent toxicity as well as cross-reactiv-
ity may negatively impact the results regardless of using the
markers for a negative [50,51] or positive selection [52]. Addi-
tionally, stochastic activation of antigenic markers by experimen-
tal conditions and/or epigenetic events may impact the validity of
these approaches [53–56]. Functional isolation using sphere-for-
mation also does not provide deﬁnite information on which cells
are actually propagated and how heterogeneous they are. Even
though an increased expression of CSC markers in the tumor
spheres is commonly observed, it is not always associated with
enhancement of tumor-initiated ability in vivo. These discrepan-
cies might cause over-interpretation and signiﬁcantly impair the
reproducibility of the results [48,57,58]. In addition, the xeno-
transplantation animal models frequently used for testing CSC
tumor-initiating ability in vivo also pose problems. Although
the ability to generate tumors in an inappropriate environment
is consistent with CSC hypothesis, there is a concern that the
use of different immune compromised mouse models as well asJournal of Hepatology 201various sites of transplantation and different ways of application
(e.g. with or without Matrigel, hormone pellets, etc.) may signif-
icantly impact the outcome and experimental reproducibility
[59–61].
Another fundamental question relates to the primary source
of CSC isolation. Currently, CSCs are isolated from primary can-
cers, primary tumor xenografts, and established tumor-derived
cell lines. Both primary tumor cells and cancer cell lines are
shown to possess a distinct tumor hierarchy based on the expres-
sion of surface markers and other commonly accepted CSC crite-
ria. It remains to be determined whether the clonally derived
cancer cell lines which are maintained for decades under culture
conditions retain the clinical characteristics of CSCs [48]. Never-
theless, the validity of using cancer cell lines in CSC research
has been demonstrated in the past [30,62,63]. Thus, most of the
markers which are currently used for isolating CSCs from primary
tumor samples were established and adapted from cancer cell
lines. More importantly, mechanistic studies are difﬁcult to con-
duct on primary cells, since the current technology used for
molecular proﬁling of CSCs demands in vitro expansion to obtain
a sufﬁcient amount of nucleic acids and proteins from a minute
CSC population. Another problem involves the use of heteroge-
neous and not clonally derived cells from primary tissues for line-
age tracking and differentiation experiments. In particular, single
cell assays are particularly compromised and difﬁcult to repro-
duce. In these cases, clonally derived cell populations may help
to ensure the reproducibility of the data. At the end, the clinical
relevance of the in vitro ﬁndings should be demonstrated and val-
idated in primary tumor samples. This could involve immunohis-
tochemistry and/or gene expression analysis of tumor samples.
As outlined in many studies on CSC, a combination of different
approaches seems to be optimal for critical evaluation of the clin-
ical relevance of the experimental ﬁndings.Regulation of cancer stem cells in hepatocarcinogenesis
Considerable advances in the ﬁeld of ‘‘-omics” over the last dec-
ade have unraveled key molecular mechanisms of hepatocarcino-
genesis [38,64–68]. Interestingly, many of the identiﬁed
regulatory pathways are known to be involved in stem cell main-
tenance as well as self-renewal and pluripotency, including WNT/
b-Catenin, TGF-b, MET, Hedgehog, MYC, p53, EGF, etc. The disrup-
tion of these functionally overlapping pathways showed a fre-
quent association with prognosis in liver cancer [14,69–74].
Moreover, several studies have correlated the clinical course of
HCC patients with cellular origin of tumors [66,75,75,76]. Finally,
a strong association with bad prognosis was found in HCCs char-
acterized by hepatic progenitor cell origin [38,75].
Growing evidence indicates that many if not all signaling
pathways identiﬁed in liver cancer are also active in the prospec-
tively isolated liver CSC [14,15] supporting the idea that molecu-
lar heterogeneity of HCC originates in the CSC compartment.
Therefore, the common pathways could serve as novel prognostic
biomarkers and represent targets for the development of new
therapeutic strategies to speciﬁcally eradicate CSCs.WNT/b-catenin
WNT signaling has been studied intensively in embryonic devel-
opment. The response of cells to WNT signaling is both tissue-0 vol. 53 j 568–577 571
Table 2. CSC signaling in liver cancer.
Signaling CSC marker Inhibitors (under
investigation)
References
WNT/
b-Catenin
EpCAM, CD133, SP RNAi, mAB [25,38,42]
TGF-b Human HCC,
EpCAM
NSC74859
targeting IL6/
STAT3
[34,38,95,96]
NOTCH CD133 c-secretase
inhibitors, mAB
[25]
Hedgehog CD133 Cyclopamine, mAB [25]
Pluripotency EpCAM, CD133, SP,
human HCC
RNAi [25,34,42]
RNAi, RNA interference machinery; mAB, monoclonal antibody.
Reviewand content-dependent and involves survival, proliferation, and
change in cell fate. Disruption of WNT signaling results from both
genetic and epigenetic changes and is associated with a range of
diseases and is frequently found in many cancers, especially
colon cancer and HCC [77–79]. Disrupted WNT signaling by
mutational and non-mutational events (e.g. cross-talk with other
signaling pathways such as TGF-b) is observed in around one
third of all HCCs which emphasizes the importance of this path-
way for hepatocarcinogenesis [80]. Indeed, activation of WNT sig-
naling has been demonstrated in different prospectively isolated
CSCs [81,82]. In the liver, elevated expression of WNT and its
downstream mediators was reported in CD133+ and EpCAM+
liver CSCs [25,34,38] Additionally, gene expression proﬁling of
SP cells from two different HCC cell lines showed activation of
this pathway [41,42]. However, the speciﬁc targeting of this path-
way is problematic due to the multiplicity of the involved and
highly conserved proteins and pleiotropic ways of activation
[18,77,83]. Nevertheless, RNAi mediated knockdown of b-catenin
resulted in decreased proliferation, colony formation, migration,
and drug resistance of lung cancer stem cells (Table 2). The
knockdown of the downstream target EpCAM in liver CSC had a
similar effect [34,82].MYC
The proto-oncogene MYC is involved in the regulation of 15% of
all genes. MYC is activated by diverse stimuli including WNT,
Hedgehog, and MAPK/ERK. MYC effects on target genes are med-
iated by various genetic and epigenetic mechanisms, including
DNA-methylation and chromatin remodeling [84,85]. MYC has a
broad impact on almost all cellular processes, such as prolifera-
tion, apoptosis and differentiation, and is involved in maintaining
stem cell pluripotency [86]. Overexpression and structural mod-
iﬁcations of the MYC gene are frequent events in many cancers
[68,87]. Recent studies conﬁrmed the crucial role of MYC in both
murine and human hepatocarcinogenesis, particularly in the pro-
cess of malignant transformation [74,88,73]. High levels of MYC
were found in the SP of colon cancer cells [89,90] whereas knock-
down of c-Myc by lentiviral shRNA signiﬁcantly reduced prolifer-
ation concomitantly with cell cycle arrest and increased
apoptosis. The role of MYC in the prospectively isolated liver
CSC has not been systematically assessed and needs further eval-
uation. The dual oncogenic and pro-apoptotic functions of MYC
indicate that therapeutic targeting of MYC should be conducted
with caution [91].572 Journal of Hepatology 201TGF-b
The members of TGF-b family are under intensive investigation
due to their importance both for stem cells and cancer [92,93].
TGF-b is also found to have a crucial role in maintaining the CSCs
in different tumors including liver cancer [15,93,94,92,95]. Mish-
ra and collegues showed that lack of responsiveness to the TGF-b
signaling pathway in liver stem cells led to the generation of liver
CSCs and that disrupted TGF-b signaling is observed in the poten-
tial CSC from human HCCs. The results were conﬁrmed in the
EpCAM+ CSCs isolated from liver cancer cell lines [34,95].
Recently, it was demonstrated that the targeting of this pathway
using indirect modulation of IL6/STAT3 appeared to be effective
for eradication of CSC [96] as also discussed in the recent reviews
on this topic [15,94,92].
Notch
The evolutionary conserved NOTCH pathway is involved in many
developmental processes, including differentiation, fate decision
(e.g. epithelial–mesenchymal–transition), proliferation, apopto-
sis, and cell adhesion [97]. In the liver, it is involved in develop-
ment by coordinating biliary epithelial cell differentiation and
morphogenesis [98]. Disrupted NOTCH signaling is recognized
in a growing number of cancers including liver cancer [97,99].
The role of NOTCH has been also demonstrated in putative CSCs
isolated from liver and other cancers [25,100]. Increased expres-
sion of genes involved in this pathway has been shown in CD133+
liver cancer cells as compared to the CD133 counterpart. Inhib-
itors of the NOTCH pathway are currently under investigation in
clinical trials for solid tumors although the role in liver cancer
remains unclear [101].
Hedgehog
Hedgehog signaling is crucial for many cellular processes
involved in cell and stem cell biology. Activation of this pathway
is observed in variety of human cancers, including basal cell car-
cinomas (BCCs), medulloblastomas, leukemia, gastrointestinal,
lung, ovarian, breast, prostate, and hepatobiliary malignancies
[102,103] Activation of the Hedgehog pathway has been demon-
strated in CD44+CD24+EpCAM+ pancreatic CSCs, particularly at
the invasive front of tumors [37,104]. The high expression of
genes involved in this pathway was further established in highly
tumorigenic CD133+ liver CSCs [25]. Discovery of the speciﬁc
inhibitors of the hedgehog pathway seems promising for target-
ing liver CSC.BMI
BMI1 is a part of the polycomb group genes (PcG) that are highly
conserved throughout evolution. BMI acts as an epigenetic chro-
matin modiﬁer and is known for its contribution to embryonic
and stem cell self-renewal program [105]. It is frequently overex-
pressed in different cancer types and disruption of BMI1 signaling
has been linked to the activation of the hedgehog pathway in
some cancers, e.g. medulloblastoma [106,107]. Further, BMI1
upregulation is associated with malignant transformation and
acquisition of the malignant phenotype in HCC [108]. Aberrant
BMI1 expression is reported in many CSC populations and it
has been shown to have a critical role in maintaining and propa-0 vol. 53 j 568–577
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gating the SP population in liver cancer. BMI1 is also highly
expressed in CD133+ liver CSCs. The role of BMI1 in liver CSC
maintenance is further conﬁrmed by the dramatic effect caused
by BMI1 knockdown in SP cells. BMI1 silencing completely abol-
ished the tumorigenicity of SP cells [25,43,109].Epigenetic regulation of CSC
Epigenetics can be deﬁned as modiﬁcations of the DNA and/or
associated proteins other than DNA sequence variation carrying
information content during cell divisions [110]. The importance
of the epigenetic mechanisms is best illustrated by the fact that
the epigenome undergoes profound changes from the zygote to
the somatic tissues while the DNA remains the same. It is there-
fore not surprising that abnormal epigenetic regulation is
increasingly recognized as one of the fundamental mechanisms
underlying many human diseases including cancer [111]. For
example, it is well known that DNA methylation changes are
the early events in carcinogenesis leading to allelic imbalances
and cancer progression [112]. The early occurrence of DNA meth-
ylation changes during carcinogenesis starting from the preneo-
plastic stage implies that epigenetic changes may arise in stem
cell compartments either preceding and/or predisposing to
genetic changes and whereby leading to tumor heterogeneity.
This notion is supported by a recent study suggesting that DNA
methylation changes may shift the functional balance from stem
cell homeostasis to cancer [113]. Consistent with this, epigenetic
proﬁling pointed to a stem cell origin in some cancers [114,115].
The importance of epigenetics has been also recognized in liver
cancer [20]. Changes in the DNA methylation patterns, including
global hypomethylation and promoter hypermethylation, were
established as frequent and early events during human liver
oncogenesis [116]. Furthermore, we recently demonstrated that
these changes strongly correlate with the biological behavior of
the tumors and the clinical outcome of cancer patients [117].
Notably, patients with tumors displaying progenitor cell proper-
ties presented the worse prognosis [75].
Our own work on epigenetically modiﬁed SP cells using a
DNMT1-inhibitor zebularine provides further evidence for the
signiﬁcance of epigenetic mechanisms for liver CSCs ([118];
own unpublished data). We observed that inhibition of DNA
methylation in human liver cancer derived cell lines resulted in
increase of highly tumorigenic cells within the SP fraction. Fur-
thermore, global transcriptomic analysis of the SP cells allowed
generation of a common SP-gene expression signature capable
of predicting the clinical outcome (survival and recurrence) of
HCC patients.
MircoRNA
MircoRNAs (miRs) are small non-coding RNAs involved in the
posttranscriptional control of hundreds of target genes, and are
recognized as key regulators in numerous cellular processes
including differentiation and pluripotency. Aberrant expression
of this class of molecules considerably contributes to cancer
development, progression, and generation of metastasis [119].
In liver carcinogenesis, miRs have been found to have both tumor
suppressive (miR-122, miR-26, miR-223) and oncogenic (miR-
221, miR-222) activity [120–124]. Recently, a crucial role of miRs
has been established in regulating CSC suggesting the possibilityJournal of Hepatology 201of miR-directed CSC eradication [125–128]. Currently there is
only one study focusing on miRs in liver CSCs which suggests that
miR-181 may be an attractive target for therapy by decreasing
EpCAM+ liver CSCs [129]. More results are expected from this
emerging and exciting ﬁeld in CSC research.CSC and self-renewal
The transcription factors OCT4, SOX2, KLF4 and MYC are well
known for their role in mediating and sustaining adult and
embryonal stem cell self-renewal and pluripotency [86]. In addi-
tion, emerging evidence emphasizes misregulation of these genes
in many cancers [130,131]. Several recent investigations have
used global approaches to compare the transcriptional programs
operating in embryonic stem cells (ESC) and adult tissue stem
cells in the context of different cancers [132–134]. Despite differ-
ent experimental approaches, activation of ESC-like gene sets was
consistently observed in aggressive human epithelial cancers,
including liver cancer [133,134]. Interestingly, the ESC signature
published by Ben-Porath and colleagues showed no association
with tumor-initiating CD44+/CD24 breast CSC [134]. In contrast,
the MYC oncogene identiﬁed in the ESC-like module by Wong
et al. had an essential impact on both tumor initiation and reac-
tivation of the ESC-like module in normal and cancer cells [133].
These data highlight the importance of the MYC gene in both nor-
mal and cancer stem cell biology.
Activation of OCT4 in putative liver CSCs with misregulated
TGF-b signaling conﬁrmed the importance of pluripotency mark-
ers for human HCC [95]. Furthermore, prospectively isolated
EpCAM+ and CD133+ cells also exhibited activation of pluripoten-
cy associated genes [25,34]. Together, these data suggest that
similar albeit not identical processes controlling self-renewal
and pluripotency in stem cells are also present in the CSC. More
work is needed to understand the mechanisms and regulatory
pathways involved in CSC self-renewal.Cancer stem cells and metastasis
The incidence of metastases impacts the prognosis of most can-
cers and accounts for many cancer related deaths. Key events in
this process are acquisition of the ability to migrate, invade
through the extracellular matrix into the blood vessels, escape
form immune surveillance, and extravasate at the target tissue
[135,136]. The same properties are ascribed to the CSC are and
thought to be regulated by the signals from their microenviron-
ment/niche [12,137,138]. Although mechanisms leading to
metastasis are yet to be fully understood, the epithelial-mesen-
chymal transition appears to play a pivotal role [23]. Several
studies attempting to identify circulating and metastatic CSC
were able to reveal the metastatic potential of CSC, their contri-
bution to neo-vascularisation, and identiﬁed mechanisms leading
to immune-escape [139–142]. Other groups demonstrated that
CSCs and/or CSC gene signatures strongly correlate with patient
prognosis [143,144]. Although the contribution of liver CSCs to
metastasis formation is unclear, early recurrence frequently takes
place after curative resection or transplantation and is attributed
to metastatic tumor cells [145–147]. Yang and colleagues demon-
strated that the metastatic cells were indeed CD90+ CSCs [31].
Resident and circulating tumorigenic CD90+CD45- cells were0 vol. 53 j 568–577 573
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identiﬁed in most of the investigated HCC patients but not in cir-
rhotic or disease free control patients.Clinical implications and future challenges in CSC research
Implicit in the CSC hypothesis is the assumption that cancer ini-
tiation, local recurrence, metastasis, and therapy resistance are
the fundamental domains of the CSC. Consequently, CSCs should
be the principal target of therapy. However, the traditional cancer
therapies which primarily target rapidly dividing and most likely
well differentiated tumor cells, would fail to eliminate CSCs. This
may explain the disappointing results of current cancer therapies
(chemotherapy, irradiation, and immunotherapy), which most
often lead to tumor relapse [148]. It is therefore important to
emphasize the necessity to explore the susceptibility of CSCs to
existing therapies in combination with the disruption of key
‘‘stemness” pathways controlling self-renewal, pluripotency,
radio-chemoresistance, and neo-angiogenesis [11].
Other novel and important directions for effective therapy
may include disruption of the tumor niche essential for CSC
homeostasis [149–151] or depletion of CSCs by forced differenti-
ation. The latter approach has been shown to be promising
against brain tumors and leukemia, using BMP and retinoic acids
as differentiating agents, respectively [152–154]. Another com-
prehensive study employed high-throughput screening to vali-
date the targeting of differentiation as a speciﬁc therapy against
breast CSCs. The highest efﬁciency was achieved by a compound
that increased differentiation of tumor cells [155]. Experimental
evidence also exists suggesting that differentiation forced by
transduction of liver enriched transcription factor HNF4a might
be effective against liver cancer [156]. Hepatoma cells transduced
with HNF4adisplayed a decrease in ‘‘stemness” gene expression
and a reduced number of CD133+ and CD90+ as well as a dramatic
reduction of tumorigenicity and metastatic potential. However,
more work is needed for the accurate assessment of the power
of this approach to exclude inadequate differentiation of non-tar-
get cells [15].
Direct targeting of CSC-speciﬁc surface markers, such as
CD133, CD90, EpCAM and CD44, may be a powerful therapeutic
approach to speciﬁcally eliminate liver CSC. However, the prog-
nostic relevance of the available surface markers remains contro-
versial in histopathological evaluation of HCC as well as other
cancers [157–159]. Nevertheless, RNAi targeting of EpCAM signif-
icantly decreased the CSC pool and reduced both the tumorige-
nicity and invasive capacity of liver CSCs [34]. Since EpCAM
expression is a downstream target of WNT/b-catenin, these
results may have implications for development of novel target
therapies. Finally, there is experimental evidence that reveals
that targeting of pluripotency genes involving OCT4 and NANOG
could be potentially useful for the speciﬁc eradication of CSCs
[160–162]. Importantly, all of these transcription factors also
mediate ‘‘stemness” of the normal stem cells. Therefore, the
effects of their targeting should be critically evaluated. A thera-
peutic strategy utilizing a combination of traditional anticancer
therapy eradicating the bulk of tumor cells with speciﬁc CSC tar-
gets may be the most promising approach.
In summary, accumulating evidence suggests a hierarchic
organization of liver cancer. Over the last years, substantial pro-
gress has been made in the prospective isolation and identiﬁca-
tion of key signaling pathways which deﬁne the unique574 Journal of Hepatology 201properties of liver CSCs, including WNT, TGF-b, NOTCH, and
Hedgehog. Current results strongly indicate the advantage of tar-
geting CSCs to improve the limited efﬁciency of existing thera-
pies. More work, particularly utilizing integrative whole
genomic and epigenomic approaches, is needed to advance our
knowledge on CSCs and develop effective anti-CSC therapy.Acknowledgements
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